<unk>  is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat people one year of age and older with high-risk neuroblastoma in bone or bone marrow whose tumor did not respond to or has come back after previous treatments and has shown a partial response, minor response, or stable disease to prior therapy.
Naxitamab
Tafasitamab
Donanemab
Obiltoxaximab
Atoltivimab
Sutimlimab
Sotrovimab
Regdanvimab